Floatz logo

Pembrolizumab

Myxofibrosarcoma (MFS)

Epkinmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the Myxofibrosarcoma (MFS) cohort.

Asset / SponsorPhaseRating
Cab-Axl-Adc
BioAtla, Inc.
Phase 1/2CCC
okn4395
Epkin
Phase 1CC

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →